Whoami1989
Posted - 4 hours ago
$EDIT the most pathetic stock to invest in
Quickdood
Posted - 4 hours ago
$EDIT Tomorrow the updates provided during the call should matter more than the earnings but if anyone is interested I attached the quarterly estimates as a picture. Looks like consensus is a 66 cent loss. Earnings are reported before market open. Watch out for tricks!
russellkbrett
Posted - 5 hours ago
@nrp Same. It has been a slow melting ice cube since early March on most the the CRISPR stocks on very low volume. I think shorts just kept hitting a very thin bid as long as it works but that doesn't work forever. 8 consecutive weeks down and there's some 19M shares short now on $EDIT with no downward revisions since the last ER. Stifel still @ $17 (from $9 upgraded last Sept) with positive updates since. No reason this should be below last years all-time-low.
AivelX
Posted - 5 hours ago
đź’ˇ #AivelX Tomorrow Premarket Earnings Insights (1/2) $ACMR - Ref.Earnings: 16 Gap Up Prob.: 94%, max +6.3%, min -0.6%, avg +1.3% Avg Low vs Open: -1.4% Avg Close vs Low: +2.9% Avg Low-High %: 4.7% 5 Days Later: 69% new highs, 56% new lows Earnings Day: 44% broke 28 (+2%) $EDIT - Ref.Earnings: 40 Gap Up Prob.: 80%, max +18%, min -4.1%, avg +1.5% Avg Low vs Open: -2.2% Avg Close vs Low: +5.9% Avg Low-High %: 8.7% 5 Days Later: 55% new highs, 70% new lows Earnings Day: 30% broke 6.3 (+10%) $SUN - Ref.Earnings: 438 Gap Up Prob.: 40%, max +9.6%, min -18.5%, avg -1% Avg Low vs Open: -3.4% Avg Close vs Low: +1.8% Avg Low-High %: 5.1% 5 Days Later: 45% new highs, 74% new lows Earnings Day: 13% broke 57 (+3%) Get Early Access to our Live platform for more insights about hundreds of tickers, link in bio âś… #AI #Python
russellkbrett
Posted - 5 hours ago
@nrp You'd never know $BEAM even reported this morning looking at the anemic volume over there. Did well over 7M total on the last report (Feb 27th). That stock still has more than 13M shares held short and is not even doing 1M total volume today. Share price was cut in half from the highs of the last ER. My take is that too much of the floats now are held short within the entire group ($CRSP $EDIT $PRME VERV CRBU) that there's not enough available shares in the daily churn to provide the liquidity needed to cover all without moving the price up substantially. Would be nice to see a big open sustain an upside momentum in order to get them more motivated.
Do_The_Opposite
Posted - 5 hours ago
$EDIT ER leaking, I want to see close to 6 close today
Do_The_Opposite
Posted - 5 hours ago
$EDIT Surprised cannot even get a penny excitement on ER for tomorrow
epsguid
Posted - 6 hours ago
Options are priced for bigger-than-average #earnings move for $EDIT reporting 5/8/2024 via @eWhispers #volatility http://eps.sh/s/edit
Do_The_Opposite
Posted - 6 hours ago
$EDIT So @Zippy99 said we hit 7.77 tomorrow
Do_The_Opposite
Posted - 6 hours ago
$EDIT I decided to buy more before WE tomorrow. Look at the stocks performance on ER day. Pretty impressive overtime
Do_The_Opposite
Posted - 6 hours ago
$EDIT Does Wall Street Bets still exist? If so someone tell them this is a prime candidate to Squeeze
Whoami1989
Posted - 6 hours ago
$EDIT this fpos cant hold any gain. pumpers please tell ke why
Do_The_Opposite
Posted - 6 hours ago
$EDIT I wonder when the institutions are going to cover
Do_The_Opposite
Posted - 7 hours ago
$EDIT Shorting this little piggy with everyone else....
Do_The_Opposite
Posted - 7 hours ago
$EDIT looking to pick the baby up tomorrow at 5.10
nrp
Posted - 8 hours ago
$EDIT $Beam reported and stock has performed very well. I feel comfortable with tomorrows report. I added more today.
DoctrBenway
Posted - 10 hours ago
$EDIT Added @ 5.62
777Dog
Posted - 10 hours ago
$EDIT Good news...technology works...magnificent results....Biblical Bad news...tutes own over 70% so retail just tagging along waiting for payday... When will the tutes drive it above $20 bucks...I dunno, but they will if they aren't sitting on it for a buyer...
donkeydink
Posted - 10 hours ago
$EDIT makes the blind see (*price falls*) 🤦🏻‍♂️
Quickdood
Posted - 11 hours ago
$EDIT Very low volume this morning.
Quickdood
Posted - 11 hours ago
@paidBearByTheIMF Very good question, I don't have a solid answer but I do have some guesses. Guess 1: This stock is part of a basket of stocks that are suppose to be interest rate sensitive. When we get high inflation news this tanks. In this scenario EDIT would not be getting individual attention, it is just being shorted as part of a basket. Guess 2: Market makers are hoping price matters more to retail than news. In addition they are probably hoping retail doesn't really follow or understand the news on $EDIT. They hope retail will capitulate based on price alone. Those are my guesses, maybe reality is a hybrid of those two guesses. Either way I think patients will be rewarded.
nrp
Posted - 11 hours ago
$EDIT I can't believe this is a 6.00 dollar stock.
Do_The_Opposite
Posted - 11 hours ago
$EDIT Well with ER tomorrow and over 7 tomorrow will we see at least 6 today.
Quickdood
Posted - 11 hours ago
$EDIT The good news just keeps on rolling in. We're witnessing the birth of the industry that may cure all genetic disease. Investing aside, this is a very exciting time to be a human.
burbs88
Posted - 14 hours ago
$CRSP $EDIT $CRBU
Entire sector has similar charts and is about to reverse. These are my favorites. Ridiculous long term upside on all of these, with CRSPR theraputics my favorite lower risk decade long hold. Shorter term, CRBU can absolutely fly within only 1 month and EDIT within 1 year. My gains will likely go back into CRSPR theraputics long term.
BoeingStingray
Posted - 19 hours ago
Participants of pioneering CRISPR gene editing trial see vision improve | OHSU News $Crsp $edit $beam $ntla https://news.ohsu.edu/2024/05/06/participants-of-pioneering-crispr-gene-editing-trial-see-vision-improve
777Dog
Posted - 22 hours ago
$EDIT Oh my...CNN just picked up the story with in-depth praise of Editas...link below including this nugget: [The latest results from the Phase 1/2 trial support moving forward with a Phase 3 trial and then ultimately registering the therapy for possible FDA approval, Pierce said. “We are working with Editas to identify an additional commercial partner for Phase 3 studies. We’re actually hoping this publication will stimulate interest in the biotech and pharma communities about that,” Pierce said.] Buckle up... https://www.cnn.com/2024/05/06/health/gene-editing-blindness-study-scn/index.html
777Dog
Posted - 22 hours ago
$EDIT They should make these therapies profitable for these rare diseases...$$$ is the obvious corporate attraction for the more common diseases like glaucoma, but nobody can deny the proof of principle aspect of this study as well as the simple fact that Editas technology works IN VIVO and improves lives... "This trial shows CRISPR gene editing has exciting potential to treat inherited retinal degeneration," said Mark Pennesi, M.D., Ph.D., a corresponding author on the paper, an ophthalmologist and Oregon Health & Science University's lead scientist for the Phase 1/2 BRILLIANCE trial. "There is nothing more rewarding to a physician than hearing a patient describe how their vision has improved after a treatment. One of our trial participants has shared several examples, including being able to find their phone after misplacing it and knowing that their coffee machine is working by seeing its small lights."
777Dog
Posted - 22 hours ago
$EDIT The two kids were from Penn...let's mark this success in the "medical miracles" column...home run... “Our patients are the first congenitally blind children to be treated with gene-editing, which significantly improved their ability to see things like daylight"... " This trial represents a landmark in the treatment of genetic diseases, in specific, genetic blindness, by offering an important alternative treatment, when traditional forms of gene therapy, such as gene augmentation, are not an option.”... There were no events of side effects reported in the study or any “dose-limiting toxicities”... Leber congenital amaurosis (LCA) is the most common cause of inherited blindness in childhood. https://www.pennmedicine.org/news/news-releases/2024/may/gene-editing-improves-sight-in-children-treated-for-blindness
